Market Overview

New Results From Phase 2 Clinical Trial of TG-1101 in Combination With Ibrutinib Confirms Robust Clinical Activity With a Favorable Safety in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News FDA Press Releases

 

Related Articles (TGTX)